Presented in part at the National Society of General Internal Medicine meeting, San Diego, Calif, May 3, 2001.
Atherosclerotic Risk Factor Reduction in Peripheral Arterial Disease
Results of a National Physician Survey
Version of Record online: 11 DEC 2002
Journal of General Internal Medicine
Volume 17, Issue 12, pages 895–904, December 2002
How to Cite
Mc Grae McDermott, M., Hahn, E. A., Greenland, P., Cella, D., Ockene, J. K., Brogan, D., Pearce, W. H., Hirsch, A. T., Hanley, K., Odom, L., Khan, S., Criqui, M. H., Lipsky, M. S. and Hudgens, S. (2002), Atherosclerotic Risk Factor Reduction in Peripheral Arterial Disease. Journal of General Internal Medicine, 17: 895–904. doi: 10.1046/j.1525-1497.2002.20307.x
- Issue online: 11 DEC 2002
- Version of Record online: 11 DEC 2002
- peripheral vascular disease;
- quality of care;
- cardiovascular disease
OBJECTIVE: Individuals with peripheral arterial disease (PAD) have a 3- to 6-fold increased risk of coronary heart disease and stroke compared to those without PAD. We documented physician-reported practice behavior, knowledge, and attitudes regarding atherosclerotic risk factor reduction in patients with PAD.
DESIGN: National physician survey.
PATIENTS/PARTICIPANTS: General internists (N = 406), family practitioners (N = 435), cardiologists (N = 473), and vascular surgeons (N = 264) randomly identified using the American Medical Association's physician database.
MEASUREMENTS AND MAIN RESULTS: Physicians were randomized to 1 of 3 questionnaires describing a) a 55- to 65-year-old patient with PAD; b) a 55- to 65-year-old patient with coronary artery disease (CAD), or c) a 55- to 65-year-old patient without clinically evident atherosclerosis (no disease). A mailed questionnaire was used to compare physician behavior, knowledge, and attitude regarding risk factor reduction for each patient. Rates of prescribed antiplatelet therapy were significantly lower for the patient with PAD than for the patient with CAD. Average low-density lipoprotein levels at which physicians “almost always” initiated lipid-lowering drugs were 121.6 ± 23.5 mg/dL, 136.3 ± 28.9 mg/dL, and 149.7 ± 24.4 mg/dL for the CAD, PAD, and no-disease patients, respectively (P < .001). Physicians stated that antiplatelet therapy (P < .001) and cholesterol-lowering therapy (P < .001) were extremely important significantly more often for the CAD than for the PAD patient. Perceived importance of risk factor interventions was highly correlated with practice behavior. Compared to other specialties, cardiologists had lowest thresholds, whereas vascular surgeons had the highest thresholds for initiating cholesterol-lowering interventions for the patient with PAD. Cardiologists were significantly more likely to report “almost always” prescribing antiplatelet therapy for the patient with PAD than were all other physicians.
CONCLUSIONS: Deficiencies in physician knowledge and attitudes contribute to lower rates of atherosclerotic risk factor reduction for patients with PAD. Reversing these deficiencies may reduce the high rates of cardiovascular morbidity and mortality associated with PAD.